Studies and Documentation

Clinically Proven Safety and Efficacy of Milmed/AgeViva™

Over 1,500 people have used Milmed/AgeViva for more than 10 years, even though we have not had active sales. Many have used the product in our human studies. Scientific articles based on these studies have been published, see clinical studies. In all our published articles, our product is called Milmed. When we market our product, we use our longevity brand AgeViva™.

The efficacy and safety of Milmed/AgeViva have been followed in proof-of-concept studies. In several of the studies, one group of volunteers received Milmed/AgeViva and the other group received a placebo. The results show that everyone who received Milmed/AgeViva noted a significant effect.. In the placebo group, two people felt a very small effect, while the remaining people noted no effect at all.

A number of toxicity studies have been carried out on Milmed/AgeViva which confirm the product's safety, studies carried out under the direction of Professor Rita Businaro.

Links to studies - Inflammations, toxicity.

Journal of Toxicology and Pharmacology Milmed Yeast Alters the LPS-Induced M1 Microglia Cells Anti-inflammatory Action Restoration of MPTP-induced deficits AgeViva Modulates Inflammatory Responses, Autophagy, and Mitochondrial Homeostasis in BV-2 Cells and C. elegans The Probiotic Yeast, Milmed, Promotes Autophagy
Targeting the Biology of Ageing

AgeViva supports mitochondrial function, reduces oxidative stress, and promotes healthy immune regulation. Together, these actions aim to preserve homeostasis—the body’s capacity to keep internal systems in balance despite ageing and external stress.
Longevience AB
Org.nr:559500-0778
info@longevience.com